Although BCR::ABL1 fusions in patients with T-ALL are rare, high in vitro and ex vivo susceptibility to dasatinib in up to 30% of non-BCR::ABL1-rearranged T-ALL cases was recently reported [99,100]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.